Clinical trial evaluates heterologous prime/boost regimens in preventative HIV vaccination
1-Oct-2014 - Almost 40 million people worldwide live with HIV/AIDS, with an estimated 2.5 million new
cases per year. Therefore, there has been a large global effort to develop an effective vaccine against the virus. HIV-1 vaccine
development has been challenging but recent clinical trials have been promising. A new study in the Journal of Clinical
Investigation discusses the results from a clinical trial that evaluated the immune response following different
HIV vaccine regimes. Nicole Frahm and colleagues tested prime-boost regimes combining a New York vaccinia
HIV clade B (NYVAC-B) vaccine and a recombinant adenovirus 5-vectored (rAd5-vectored) vaccine in a
cohort of healthy volunteers. Individuals that received the rAd5-vectored vaccine followed by
the NYVAC-B vaccine exhibited the strongest anti-HIV immune responses. A regime in which
individuals received the NYVAC-B vaccine prior to the rAd5-vectored vaccine was not
as effective. The results from this study will be important for the design of
further clinical trials to evaluate potential HIV-1 vaccine regimes.
TITLE: HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial
AUTHOR CONTACT: Nicole Frahm
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Phone: 206.667.6268; Fax: 206.667.6136; E-mail: nfrahm@fhcrc.org
View this article at: http://www.jci.org/articles/view/75894?key=30bb5f40d024b357fffa
Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
@jclinicalinvest
Source: http://www.eurekalert.org/pub_releases/2014-10/joci-cte100114.php
For more HIV and AIDS News visit...
Positively Positive - Living with HIV/AIDS:
HIV/AIDS News
|
